Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The answer from PTSC to the USPTO contingency is .....

It depends on what co. we do M or A with. If we merge with a co. that could use some of the J's patents it could save us millions of dollar by not having to license them. It is my opinion that a co. has already been selected for a M or A and that the new guys on board knew BEFORE joining what they intend to do. GL, ads

PS I just wanted to mention that RG's statement about moving the co. toward more R&D was very positive, IMHO.

Share
New Message
Please login to post a reply